Nomenclature in NEN—from classification to clinic
WHO Grade | Mitotic Counta | Ki-67 Index % |
---|---|---|
G1 NET | <2 | ≤2% |
G2 NET | 2–20 | 3–20 |
G3 NEC | >20 | >20 |
Systemic treatment strategies for advanced NET
Study | Setting | Prim. EP | Outcome |
---|---|---|---|
Octreotide vs. Placebo (PROMID) Rinke 2009, JCO [7] | Midgut or unknown origin NET (non-functioning and functioning) | TTP | 14.3 m vs. 6 m (HR 0.34, 95% CI 0.20–0.59) |
Lanreotide vs. Placebo (CLARINET) Caplin 2014, NEJM [8] | Ki-67 < 10% enteropancreatic or unknown origin NET (non-functioning) | PFS | Not reached vs. 18 m (HR 0.47, 95% CI 0.30–0.73) |
Everolimus vs. Placebo (RADIANT-3) Yao 2011, NEJM [10] | Progressive disease pancreatic NET | PFS | 11 m vs. 4.6 m (HR 0.35, 95% CI 0.27–0.45) |
Everolimus vs. Placebo (RADIANT-4) Yao 2016, Lancet [11] | Progressive disease lung or GI NET (non-functioning) | PFS | 11 m vs. 3.9 m (HR 0.48, 95% CI 0.35–0.67) |
Sunitinib vs. Placebo Raymond 2011, NEJM [21] | Progressive disease pancreatic NET | PFS | 11.4 m vs. 5.5 m (HR 0.42, 95%CI 0.26–0.66) |
Streptozotocin + Doxorubicin + Fluorouracil Kouvaraki 2004, JCO [22] | Pancreatic NET | PFS/OS | 2-year PFS 41%/ 2-year OS 74% |